We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novo Nordisk (NVO) Stock Slides as Market Rises: Facts to Know Before You Trade
Read MoreHide Full Article
In the latest close session, Novo Nordisk (NVO - Free Report) was down 1% at $40.52. This change lagged the S&P 500's 1.2% gain on the day. Meanwhile, the Dow experienced a rise of 1.79%, and the technology-dominated Nasdaq saw an increase of 1.52%.
Prior to today's trading, shares of the drugmaker had gained 10.38% outpaced the Medical sector's loss of 2.77% and the S&P 500's gain of 5.15%.
The investment community will be closely monitoring the performance of Novo Nordisk in its forthcoming earnings report. The company is expected to report EPS of $0.87, down 5.43% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $11.13 billion, up 1.08% from the year-ago period.
NVO's full-year Zacks Consensus Estimates are calling for earnings of $3.37 per share and revenue of $45.22 billion. These results would represent year-over-year changes of -14.9% and -3.32%, respectively.
Any recent changes to analyst estimates for Novo Nordisk should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.46% downward. Novo Nordisk is holding a Zacks Rank of #3 (Hold) right now.
In terms of valuation, Novo Nordisk is currently trading at a Forward P/E ratio of 12.16. This expresses a discount compared to the average Forward P/E of 14.57 of its industry.
We can additionally observe that NVO currently boasts a PEG ratio of 9.65. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Large Cap Pharmaceuticals was holding an average PEG ratio of 2.32 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 169, which puts it in the bottom 31% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Novo Nordisk (NVO) Stock Slides as Market Rises: Facts to Know Before You Trade
In the latest close session, Novo Nordisk (NVO - Free Report) was down 1% at $40.52. This change lagged the S&P 500's 1.2% gain on the day. Meanwhile, the Dow experienced a rise of 1.79%, and the technology-dominated Nasdaq saw an increase of 1.52%.
Prior to today's trading, shares of the drugmaker had gained 10.38% outpaced the Medical sector's loss of 2.77% and the S&P 500's gain of 5.15%.
The investment community will be closely monitoring the performance of Novo Nordisk in its forthcoming earnings report. The company is expected to report EPS of $0.87, down 5.43% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $11.13 billion, up 1.08% from the year-ago period.
NVO's full-year Zacks Consensus Estimates are calling for earnings of $3.37 per share and revenue of $45.22 billion. These results would represent year-over-year changes of -14.9% and -3.32%, respectively.
Any recent changes to analyst estimates for Novo Nordisk should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.46% downward. Novo Nordisk is holding a Zacks Rank of #3 (Hold) right now.
In terms of valuation, Novo Nordisk is currently trading at a Forward P/E ratio of 12.16. This expresses a discount compared to the average Forward P/E of 14.57 of its industry.
We can additionally observe that NVO currently boasts a PEG ratio of 9.65. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Large Cap Pharmaceuticals was holding an average PEG ratio of 2.32 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 169, which puts it in the bottom 31% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.